World Lung 2024 – Lilly eyes a first-line KRAS triplet
Data suggest a path forward for olomorasib plus Keytruda and chemo in PD-L1 low and negative patients.
Claudin18.2 expression clouds Elevation's big reveal
Western data on EO-3021 fail to live up to the billing of a Chinese trial.
BeiGene takes a new approach to a hot target
Meanwhile Bristol’s Orum-originated project goes into the clinic, and Miltenyi looks to challenge Syndax and Kura.
Familiar targets with a twist
First-in-human study initiations feature variations on well-trodden targets, plus a minor hiccup for OncoC4.
CD47’s long goodbye
Despite magrolimab’s latest flop, efforts to target CD47 continue.
New phase 1 projects enter hot fields
Analysis of industry assets newly into human trials reveals three Car-T therapies and some familiar targets.
